

**Frovatriptan (Migard<sup>®</sup>)**

**(No. 49/03)**

**A. Menarini UK**

## **Summary of Recommendation**

4 July 2003

The Scottish Medicines Consortium (SMC) has completed its assessment of the above product and advises NHS Boards and ADTCs on its use in NHS Scotland. The recommendation is summarised as follows:

### **ADVICE**

Not recommended for use within NHS Scotland.

### **RECOMMENDATION**

Frovatriptan is another new 5-HT<sub>1</sub> agonist, which is less effective at producing rapid relief of migraine, as measured at two hours, when compared with the most commonly prescribed 5-HT<sub>1</sub> agonist. It is less expensive than other drugs in the class. However, the company provided no suitable analysis to demonstrate cost effectiveness of their product.

The licence holder has indicated their decision to resubmit.

Professor David H Lawson  
Chairman